<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40874527</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2173-9110</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Revista espanola de salud publica</Title><ISOAbbreviation>Rev Esp Salud Publica</ISOAbbreviation></Journal><ArticleTitle>[The Inclusion of Sex and Gender Perspective in the Clinical Practice Guidelines].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e202508045</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to identify the exclusion and/or types of inclusion of a sex and gender perspective in clinical practice guidelines (CPGs) in order to highlight the lack of this perspective, derived from historically male-centered model of knowledge, which is changing due to the awareness of addressing health differences between people.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search tool for web documents (scraping) was applied to analyze the CPGs catalogue of the National Health System (by Gu&#xed;aSalud) automatically and free of researcher bias. Scraping was able to search key words and contextualize them within the document. A quantitative and qualitative analysis was carried out on the output databases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 21 CPGs reviewed, 11 did not incorporate evidence on differences or similarities between men and women. Those that included some evidence did so in different ways: 2 excluded men, 1 included examples of sex, gender and intersectionality, 3 included sex or gender evidence, 3 used gender marked language, and 1 showed intersectionality without a sex/gender focus in its wording.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The 10 guidelines with sex and gender inclusion differ in what they consider important to evidence on health variations of the population related to sex, gender and intersectionality. Significantly, the inclusion of sex and gender seems to respond to the fact that the guide poses a relevant research question.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Ramos</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Instituto de Estudios Sociales Avanzados (IESA). Consejo Superior de Investigaciones Cient&#xed;ficas (CSIC). C&#xf3;rdoba. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gav&#xed;n Benavent</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Instituto Aragon&#xe9;s de Ciencias de la Salud (IACS). Centro de Investigaci&#xf3;n Biom&#xe9;dica de Arag&#xf3;n (CIBA). Zaragoza. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isern de Val</LastName><ForeName>Soledad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto Aragon&#xe9;s de Ciencias de la Salud (IACS). Centro de Investigaci&#xf3;n Biom&#xe9;dica de Arag&#xf3;n (CIBA). Zaragoza. Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>La incorporaci&#xf3;n de la perspectiva de sexo y g&#xe9;nero en las Gu&#xed;as de Pr&#xe1;ctica Cl&#xed;nica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Salud Publica</MedlineTA><NlmUniqueID>9600212</NlmUniqueID><ISSNLinking>1135-5727</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005783" MajorTopicYN="Y">Gender Identity</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">El objetivo de este trabajo fue conocer la exclusi&#xf3;n y/o tipos de inclusi&#xf3;n de la perspectiva de sexo y g&#xe9;nero en las gu&#xed;as de pr&#xe1;ctica cl&#xed;nica (GPC), de manera que evidenciemos la carencia de esta perspectiva hist&#xf3;ricamente, derivada de un modo del conocimiento centrado en lo masculino principalmente, y que est&#xe1; cambiando gracias a la consciencia de la necesidad de abordar las diferencias entre las personas en materia de salud.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Se aplic&#xf3; una herramienta de b&#xfa;squeda sistem&#xe1;tica sobre documentos web (scraping), para analizar las GPC del Cat&#xe1;logo de GPC en el Sistema Nacional de Salud (gestionado por Gu&#xed;aSalud) de manera autom&#xe1;tica y sin sesgos de las personas investigadoras. El scraping permiti&#xf3; buscar palabras claves y contextualizarlas dentro del documento. Sobre las bases de datos resultantes se llev&#xf3; a cabo un an&#xe1;lisis cuantitativo y cualitativo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">De las 21 GPC examinadas, 11 no incorporaban evidencias donde se se&#xf1;alaran diferencias o similitudes entre hombres y mujeres. Las que inclu&#xed;an alguna evidencia, lo hac&#xed;an de diferentes maneras: 2 exclu&#xed;an a los hombres; 1 inclu&#xed;a ejemplos de sexo y g&#xe9;nero e interseccionalidad; 3 incluyeron evidencias de sexo o g&#xe9;nero; 3 usaron lenguaje inclusivo; y 1 mostr&#xf3; interseccionalidad sin enfoque de sexo/g&#xe9;nero en su redacci&#xf3;n.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Las 10 gu&#xed;as con inclusi&#xf3;n de sexo y g&#xe9;nero presentan diferencias respecto a qu&#xe9; consideran importante constatar en cuanto a variaciones en salud de la poblaci&#xf3;n relacionadas con el sexo, el g&#xe9;nero o la interseccionalidad. Siendo importante se&#xf1;alar que la inclusi&#xf3;n de sexo y g&#xe9;nero parece responder al hecho de que la gu&#xed;a plantea una pregunta de investigaci&#xf3;n pertinente.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical practice guideline</Keyword><Keyword MajorTopicYN="N">Evidence-based practice</Keyword><Keyword MajorTopicYN="N">Gender bias</Keyword><Keyword MajorTopicYN="N">Men health</Keyword><Keyword MajorTopicYN="N">Quality Assurance in Health Care</Keyword><Keyword MajorTopicYN="N">Sex bias</Keyword><Keyword MajorTopicYN="N">Spain</Keyword><Keyword MajorTopicYN="N">Women health</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>19</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>19</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40874527</ArticleId><ArticleId IdType="pii">e202508045</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40222774</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2013-2514</ISSN><JournalIssue CitedMedium="Internet"><Volume>45 Suppl 1</Volume><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nefrologia</Title><ISOAbbreviation>Nefrologia (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>26</EndPage><MedlinePgn>1-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nefroe.2025.04.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2013-2514(25)00055-0</ELocationID><Abstract><AbstractText>To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to publish an updated Clinical Practice Guideline for detection and management of diabetic kidney disease (DKD). It is aimed at a wide audience of clinicians treating diabetes and CKD. The terminology of kidney disease in diabetic patients has evolved toward a more inclusive nomenclature that avoids underdiagnosis of this entity. Thus, the terms "diabetes and kidney disease" and "diabetic kidney disease" are those proposed in the latest KDIGO 2022 guidelines to designate the whole spectrum of patients who can benefit from a comprehensive therapeutic approach only differentiated according to eGFR range and albuminuria. Recommendations have been divided into five main areas of interest: Chapter 1: Screening and diagnosis of diabetic kidney disease, Chapter 2: Metabolic control in people with diabetes and CKD, Chapter 3: Blood pressure control in people with diabetic kidney disease, Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease, and Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD. World Health Organization (WHO) recommendations for guideline development were followed to report this guideline. Systematic reviews were carried out, with outcome ratings and summaries of findings, and we reported the strength of recommendations following the "Grading of Recommendations Assessment, Development and Evaluation" GRADE evidence profiles.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Sociedad Espa&#xf1;ola de Nefrolog&#xed;a. Published by Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montero</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: nuriamonteroperez@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveras</LastName><ForeName>Laia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Castelao</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; RICORS2040 Kidney Disease (RD21/0005/0013), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorriz</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Cl&#xed;nico Universitario de Val&#xe8;ncia, Universitat de Val&#xe8;ncia, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soler</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Research, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Fern&#xe1;ndez</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Hypertension, IIS-Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, RICORS2040, Department of Medicine, Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quero</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Carro</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario Cl&#xed;nico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Sancho</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Nutrition, Complex Hospitalari Universitari Moises Broggi, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goicoechea</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital General Universitario Gregorio Mara&#xf1;&#xf3;n, RICORS 2040 Kidney Disease, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorgojo Mart&#xed;nez</LastName><ForeName>Juan Jose</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Nutrition, Hospital Universitario Fundaci&#xf3;n Alcorc&#xf3;n, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nephrology, FISABIO, Hospital Universitari Dr. Peset, Universitat de Val&#xe8;ncia, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puchades</LastName><ForeName>Mar&#xed;a Jes&#xfa;s</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Nephrology Unit, Hospital Cl&#xed;nico Universitario de Val&#xe8;ncia, Universitat de Val&#xe8;ncia, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Espinosa</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Cl&#xed;nic de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabl&#xf3;n</LastName><ForeName>Nery</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario de Gran Canaria Dr. Negr&#xed;n, Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santamar&#xed;a</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Universitario Reina Sof&#xed;a, Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, C&#xf3;rdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro-Gonz&#xe1;lez</LastName><ForeName>Juan Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Research Unit and Department of Nephrology, Hospital Universitario Nuestra Se&#xf1;ora de Candelaria, Santa Cruz de Tenerife, Spain; RICORS2040 Kidney Disease (RD21/0005/0013), Instituto de Salud Carlos III, Madrid, Spain; Instituto de Tecnolog&#xed;as Biom&#xe9;dicas, Universidad de La Laguna, Tenerife, Spain; Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain. Electronic address: jnavgon@gobiernodecanarias.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GEENDIAB (Spanish Diabetic Nephropathy Study Group)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType><PublicationType UI="D016446">Consensus Development Conference</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nefrologia (Engl Ed)</MedlineTA><NlmUniqueID>101778581</NlmUniqueID><ISSNLinking>2013-2514</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009398" MajorTopicYN="N">Nephrology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Diabetic kidney diseases</Keyword><Keyword MajorTopicYN="N">Diabetic nephropathy</Keyword><Keyword MajorTopicYN="N">Enfermedades renales diab&#xe9;ticas</Keyword><Keyword MajorTopicYN="N">Guidelines</Keyword><Keyword MajorTopicYN="N">Gu&#xed;as de pr&#xe1;ctica cl&#xed;nica</Keyword><Keyword MajorTopicYN="N">Nefropat&#xed;a diab&#xe9;tica</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>14</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>14</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>13</Day><Hour>20</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40222774</ArticleId><ArticleId IdType="doi">10.1016/j.nefroe.2025.04.005</ArticleId><ArticleId IdType="pii">S2013-2514(25)00055-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39508468</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Long-term Follow-up After an Initial Episode of Diverticulitis: A 13-Year Update.</ArticleTitle><Pagination><StartPage>234</StartPage><EndPage>241</EndPage><MedlinePgn>234-241</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003587</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For patients with recurrent diverticulitis, the trigger to proceed to elective sigmoid colectomy is unclear. Current clinical practice guidelines suggest that this is an individualized decision between surgeon and patient.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the long-term risk of diverticulitis recurrence and determine predictors of recurrent disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective case series.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary care center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive patients with CT-proven diverticulitis who presented as inpatient or outpatient between 2002 and 2008.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Incidence of diverticulitis recurrence was determined via medical record review and questionnaire.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Risk of recurrent diverticulitis or surgery for diverticulitis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 753 patients with first-time diverticulitis were identified. The patients had a mean age of 61.5 years (SD 15.3). The median follow-up was 13.2 years (interquartile range, 3.8-18.3). There were 486 patients (64.5%) alive at the time of follow-up. During the initial presentation, 29 patients (3.9%) required Interventional Radiology drainage and 37 (4.9%) required emergency surgery. Forty-three patients (5.7%) underwent elective surgery after the initial presentation and 77 (10.2%) underwent surgery after more than 1 episode. Of those who did not undergo surgery for the first episode, 353 (52.4%) experienced recurrent disease with a median time to recurrence of 2.9 years (interquartile range, 0.83-8.5 years). On multivariate analysis, female sex (HR 1.28, p = 0.04), sigmoid disease (HR 1.35, p = 0.03), smoldering disease (HR 3.17, p &lt; 0.01), length of involved segment &gt;5&#x2009;cm (HR 1.28, p = 0.04), and maximum fat stranding diameter &gt;1.8&#x2009;cm (HR 1.29, p = 0.03) were associated with disease recurrence. Kaplan-Meier estimates of freedom from recurrence were 73.1% (69.6%-76.3%) at 1 year, 47.9% (44.0%-51.6%) at 5 years, and 34.6% (31.0%-38.2%) at 10 years after initial presentation.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">After a single episode of diverticulitis, the incidence of recurrence is more than 50% on long-term follow-up. Variables such as female sex, sigmoid disease, smoldering disease, length of involved segment &gt;5&#x2009;cm, and maximum fat stranding diameter &gt;1.8&#x2009;cm were associated with an increased risk of recurrence. These findings should be considered when counseling patients on the decision to proceed with elective colectomy. See Video Abstract .</AbstractText><AbstractText Label="SEGUIMIENTO A LARGO PLAZO TRAS UN EPISODIO INICIAL DE DIVERTICULITIS UNA ACTUALIZACIN DE AOS" NlmCategory="UNASSIGNED">ANTECEDENTES:En el caso de los pacientes con diverticulitis recurrente, no est&#xe1; claro el factor desencadenante para proceder a una colectom&#xed;a sigmoidea electiva. Las gu&#xed;as de pr&#xe1;ctica cl&#xed;nica actuales sugieren que se trata de una decisi&#xf3;n individualizada entre el cirujano y el paciente.OBJETIVO:Evaluar el riesgo a largo plazo de recurrencia de la diverticulitis y determinar los predictores de la enfermedad recurrente.DISE&#xd1;O:Serie de casos retrospectiva.ESCENARIO:Centro de atenci&#xf3;n terciaria.PACIENTES:Pacientes consecutivos con diverticulitis comprobada por TC que se presentaron como pacientes hospitalizados o ambulatorios entre 2002 y 2008.INTERVENCIONES:Incidencia de recurrencia de la diverticulitis determinada mediante revisi&#xf3;n de historias cl&#xed;nicas y cuestionario.MEDIDAS PRINCIPALES DE RESULTADOS:Riesgo de diverticulitis recurrente o cirug&#xed;a para diverticulitis.RESULTADOS:Se identificaron 753 pacientes con diverticulitis por primera vez. Los pacientes ten&#xed;an 61,5 a&#xf1;os (DE 15,3). La mediana de seguimiento fue de 13,2 a&#xf1;os (RIC 3,8-18,3). 486 (64,5 %) estaban vivos en el momento del seguimiento. Durante la presentaci&#xf3;n inicial, 29 (3,9 %) requirieron drenaje de IR y 37 (4,9 %) requirieron cirug&#xed;a de emergencia. 43 (5,7 %) se sometieron a cirug&#xed;a electiva despu&#xe9;s de la presentaci&#xf3;n inicial y 77 (10,2 %) se sometieron a cirug&#xed;a despu&#xe9;s de m&#xe1;s de 1 episodio. De aquellos sin cirug&#xed;a para el primer episodio, 353 (52,4 %) experimentaron enfermedad recurrente con un tiempo medio hasta la recurrencia de 2,9 a&#xf1;os (RIC 0,83-8,5 a&#xf1;os). En el an&#xe1;lisis multivariable, el sexo femenino (HR 1,28, p = 0,04), la enfermedad sigmoidea (HR 1,35, p = 0,03), la enfermedad latente (HR 3,17, p &lt; 0,01), la longitud del segmento afectado &gt; 5&#x2009;cm (HR 1,28, p = 0,04) y el di&#xe1;metro m&#xe1;ximo de la hebra grasa &gt; 1,8&#x2009;cm (HR 1,29, p = 0,03) se asociaron con la recurrencia de la enfermedad. Las estimaciones de Kaplan Meier de la libertad de recurrencia fueron del 73,1 % (69,6-76,3 %) al a&#xf1;o, del 47,9 % (44,0-51,6 %) a los 5 a&#xf1;os y del 34,6 % (31,0-38,2 %) a los 10 a&#xf1;os despu&#xe9;s de la presentaci&#xf3;n inicial.LIMITACIONES:Dise&#xf1;o retrospectivo.CONCLUSIONES:Despu&#xe9;s de un &#xfa;nico episodio de diverticulitis, la incidencia de recurrencia es superior al 50% en el seguimiento a largo plazo. Variables como el sexo femenino, la enfermedad sigmoidea, la enfermedad latente, la longitud del segmento afectado mayor de 5&#x2009;cm y el di&#xe1;metro m&#xe1;ximo de la hebra de grasa mayor de 1,8&#x2009;cm se asociaron con un mayor riesgo de recurrencia. Estos hallazgos deben tenerse en cuenta al asesorar a los pacientes sobre la decisi&#xf3;n de proceder con la colectom&#xed;a electiva. (Traducci&#xf3;n-Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anwar</LastName><ForeName>Sarah N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dombek</LastName><ForeName>Gabrielle E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Caroline E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Maggie J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munroe</LastName><ForeName>Cody</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abelson</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Jason F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Tufts University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleiman</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhnen</LastName><ForeName>Angela H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcello</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0003-2014-0302</Identifier><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003082" MajorTopicYN="Y">Colectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004239" MajorTopicYN="Y">Diverticulitis, Colonic</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>24</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>13</Day><Hour>13</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39508468</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003587</ArticleId><ArticleId IdType="pii">00003453-990000000-00790</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carr S, Velasco AL. Colon Diverticulitis. Treasure Island, FL: StatPearls; 2024.</Citation></Reference><Reference><Citation>Roberts P, Abel M, Rosen L, et al. Practice parameters for sigmoid diverticulitis. The standards Task Force American Society of Colon and Rectal Surgeons. Dis Colon Rectum. 1995;38:125&#x2013;132.</Citation></Reference><Reference><Citation>Hall J, Hardiman K, Lee S, et al.; Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis. Dis Colon Rectum. 2020;63:728&#x2013;747.</Citation></Reference><Reference><Citation>Santos A, Mentula P, Pinta T, et al. Quality-of-life and recurrence outcomes following laparoscopic elective sigmoid resection vs conservative treatment following diverticulitis: prespecified 2-year analysis of the LASER randomized clinical trial. JAMA Surg. 2023;158:593&#x2013;601.</Citation></Reference><Reference><Citation>Makela J, Vuolio S, Kiviniemi H, Laitinen S. Natural history of diverticular disease: when to operate? Dis Colon Rectum. 1998;41:1523&#x2013;1528.</Citation></Reference><Reference><Citation>Broderick-Villa G, Burchette RJ, Collins JC, Abbas MA, Haigh PI. Hospitalization for acute diverticulitis does not mandate routine elective colectomy. Arch Surg. 2005;140:576&#x2013;581.</Citation></Reference><Reference><Citation>Hall JF, Roberts PL, Ricciardi R, et al. Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis Colon Rectum. 2011;54:283&#x2013;288.</Citation></Reference><Reference><Citation>Mathilde A, Mege D, Monsinjon M, Giacca M, Panis Y. Recurrence of diverticulitis after prophylactic sigmoidectomy: an underestimated problem? Colorectal Dis. 2023;25:757&#x2013;763.</Citation></Reference><Reference><Citation>Waser A, Balaphas A, Uhe I, et al. Incidence of diverticulitis recurrence after sigmoid colectomy: a retrospective cohort study from a tertiary center and systematic review. Int J Colorectal Dis. 2023;38:157.</Citation></Reference><Reference><Citation>Salusjarvi JM, Koskenvuo LE, Mali JP, Mentula PJ, Leppaniemi AK, Sallinen VJ. Stoma reversal after Hartmann&#x2019;s procedure for acute diverticulitis. Surgery. 2023;173:920&#x2013;926.</Citation></Reference><Reference><Citation>Anwar S, Dombek GE, Hayes C. Long-term follow-up after an initial episode of diverticulitis: a 15 year update (ASCRS abstract #SA203). Dis Colon Rectum. 2024;67:e399&#x2013;e400.</Citation></Reference><Reference><Citation>Bharucha AE, Parthasarathy G, Ditah I, et al. Temporal trends in the incidence and natural history of diverticulitis: a population-based study. Am J Gastroenterol. 2015;110:1589&#x2013;1596.</Citation></Reference><Reference><Citation>Eglinton T, Nguyen T, Raniga S, Dixon L, Dobbs B, Frizelle FA. Patterns of recurrence in patients with acute diverticulitis. Br J Surg. 2010;97:952&#x2013;957.</Citation></Reference><Reference><Citation>Binda GA, Arezzo A, Serventi A, et al.; Italian Study Group on Complicated Diverticulosis (GISDIC). Multicentre observational study of the natural history of left-sided acute diverticulitis. Br J Surg. 2012;99:276&#x2013;285.</Citation></Reference><Reference><Citation>Rose J, Parina RP, Faiz O, Chang DC, Talamini MA. Long-term outcomes after initial presentation of diverticulitis. Ann Surg. 2015;262:1046&#x2013;1053.</Citation></Reference><Reference><Citation>Ho VP, Nash GM, Milsom JW, Lee SW. Identification of diverticulitis patients at high risk for recurrence and poor outcomes. J Trauma Acute Care Surg. 2015;78:112&#x2013;119.</Citation></Reference><Reference><Citation>Garfinkle R, Almalki T, Pelsser V, et al. Conditional risk of diverticulitis after non-operative management. Br J Surg. 2020;107:1838&#x2013;1845.</Citation></Reference><Reference><Citation>Choi KK, Martinolich J, Canete JJ, et al. Elective laparoscopic sigmoid colectomy for diverticulitis&#x2014;an updated look at recurrence after surgery. J Gastrointest Surg. 2020;24:388&#x2013;395.</Citation></Reference><Reference><Citation>Mizrahi I, Al-Kurd A, Chapchay K, et al. Long-term outcomes of sigmoid diverticulitis: a single-center experience. J Surg Res. 2018;221:8&#x2013;14.</Citation></Reference><Reference><Citation>Boostrom SY, Wolff BG, Cima RR, Merchea A, Dozois EJ, Larson DW. Uncomplicated diverticulitis, more complicated than we thought. J Gastrointest Surg. 2012;16:1744&#x2013;1749.</Citation></Reference><Reference><Citation>Wolff BG, Boostrom SY. Prophylactic resection, uncomplicated diverticulitis, and recurrent diverticulitis. Dig Dis. 2012;30:108&#x2013;113.</Citation></Reference><Reference><Citation>Lane JS, Sarkar R, Schmit PJ, Chandler CF, Thompson JE Jr. Surgical approach to cecal diverticulitis. J Am Coll Surg. 1999;188:629&#x2013;634.</Citation></Reference><Reference><Citation>Sung CW, Liu KL, Wang HP, et al. Author Correction: Colonic diverticulitis location is a risk factor for recurrence: a multicenter, retrospective cohort study in Asian patients. Sci Rep. 2022;12:13254.</Citation></Reference><Reference><Citation>Oh MY, Shin R, Heo SC, et al. Investigation of the clinical features and recurrence patterns of acute right-sided colonic diverticulitis: a retrospective cohort study. Ann Med Surg (Lond). 2022;81:104431.</Citation></Reference><Reference><Citation>Dickerson EC, Chong ST, Ellis JH, et al. Recurrence of colonic diverticulitis: identifying predictive CT findings-retrospective cohort study. Radiology. 2017;285:850&#x2013;858.</Citation></Reference><Reference><Citation>Poletti PA, Platon A, Rutschmann O, et al. Acute left colonic diverticulitis: can CT findings be used to predict recurrence? AJR Am J Roentgenol. 2004;182:1159&#x2013;1165.</Citation></Reference><Reference><Citation>Kim DH, Kim HJ, Jang SK, Yeon JW, Shin KS. CT predictors of unfavorable clinical outcomes of acute right colonic diverticulitis. Am J Roentgenol. 2017;209:1263&#x2013;1271.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39021619</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2659-6636</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Open respiratory archives</Title><ISOAbbreviation>Open Respir Arch</ISOAbbreviation></Journal><ArticleTitle>[Influence of Clinical Practice Guidelines on the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Data from the Registry of the Spanish Society of Pulmonology and Thoracic Surgery].</ArticleTitle><Pagination><StartPage>100334</StartPage><MedlinePgn>100334</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100334</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.opresp.2024.100334</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The objective of the study was to analyze the diagnostic process and the time until the start of treatment of patients with idiopathic pulmonary fibrosis in relation to the publication of successive clinical practice guide.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Multicenter, observational, ambispective study, in which patients includes in the idiopathic pulmonary fibrosis registry of the Spanish Society of Pulmonologist and Thoracic Surgery were analyzed. An electronic data collection notebook was enabled on the society's website. Sociodemographic and clinical variables were collected at diagnosis and follow-up of the patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">From January 2012 to december 2019, 1064 patients were included in the registry, with 929 finally analyzed. The diagnosis process varied depending on the year in which it was performed, and the radiological pattern observed in the high-resolution computed tomography. Up to 26.3% of the cases (244) were diagnosed with chest high-resolution computed tomography and clinical evaluation. Surgical biopsy was used up to 50.2% of cases diagnosed before 2011, while it has been used in 14.2% since 2018. The median time from the onset of symptoms to diagnosis was 360 days (IQR 120-720), taking more than 2 years in the 21.0% of patients. A percentage of 79.4 of patients received antifibrotic treatment. The average time from diagnosis to the antifibrotic treatment has been 309&#xa0;&#xb1;&#xa0;596.5 days, with a median of 49 (IQR 0-307).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The diagnostic process, including the time until diagnosis and the type of test used, has changed from 2011 to 2019, probably due to advances in clinical research and the publication of diagnostic-therapeutic consensus guidelines.</AbstractText><CopyrightInformation>&#xa9; 2024 Sociedad Espa&#xf1;ola de Neumolog&#xed;a y Cirug&#xed;a Tor&#xe1;cica (SEPAR). Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aburto</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Galdakao-Usansolo, Galdakao, Bizkaia, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Medicina, Universidad del Pa&#xed;s Vasco- Euskal Herriko Unibertsitatea, Pa&#xed;s Vasco, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biobizkaia, Barakaldo, Bizkaia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Portal</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Virgen del Roc&#xed;o, Sevilla, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Fabrellas</LastName><ForeName>Estrella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Consorci Hospital General Universitari de Valencia, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Medicina, Universidad de Valencia, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Sevila</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital General Universitario de Dr. Balmis, Alicante, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Medicina Cl&#xed;nica, Universidad Miguel Hern&#xe1;ndez, Elche, Alicante, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera Lara</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Doctor Peset, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollo de Miguel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Complejo Asistencial Universitario de Le&#xf3;n, Le&#xf3;n, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez Ruiz</LastName><ForeName>Jos&#xe9; Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de Salamanca, Salamanca, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Molina</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de EPID, Servicio de Neumolog&#xed;a, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safont Mu&#xf1;oz</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Cl&#xed;nico Universitario de Valencia, Valencia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godoy Mayoral</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de Albacete, Albacete, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero Ortiz</LastName><ForeName>Ana Dolores</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Virgen de las Nieves, Granada, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soler Sempere</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital General Universitario de Elche, Elche, Alicante, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo Villegas</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaud&#xf3; Navarro</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Ram&#xf3;n y Cajal, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tom&#xe1;s L&#xf3;pez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Medicina, Universidad del Pa&#xed;s Vasco- Euskal Herriko Unibertsitatea, Pa&#xed;s Vasco, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de Araba, Vitoria-Gazteiz, Araba, Vitoria-Gazteiz, Araba, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nu&#xf1;ez Sanchez</LastName><ForeName>Bel&#xe9;n</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacios Hidalgo</LastName><ForeName>Zulema</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario Virgen de Valme, Sevilla, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellares Torres</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Cl&#xed;nic de Barcelona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacrist&#xe1;n Bou</LastName><ForeName>Lirios</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital General Universitario de Ciudad Real, Ciudad Real, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieto Barbero</LastName><ForeName>Mar&#xed;a Asunci&#xf3;n</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casanova Espinosa</LastName><ForeName>Alvaro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario del Henares, Coslada, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portillo-Carroz</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cano-Jimenez</LastName><ForeName>Esteban</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Lucus Augusti, Lugo, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acosta Fern&#xe1;ndez</LastName><ForeName>Orlando</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Complejo Hospitalario Universitario de Canarias, San Crist&#xf3;bal de La Laguna, Santa Cruz de Tenerife, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legarreta</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Research Unit, Osakidetza Basque Health Service, Galdakao-Usansolo University Hospital, Galdakao, Bizkaia, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biosistemak Kronikgune Institute for Health Services Research, Galdakao, Bizkaia, Espa&#xf1;a.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network for Research On Chronicity, Primary Care, and Health Promotion (RICAPPS), Galdakao, Bizkaia, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valenzuela</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de La Princesa, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>en representaci&#xf3;n del Grupo SEPAR-IPF National Registry</CollectiveName></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Influencia de las gu&#xed;as de pr&#xe1;ctica cl&#xed;nica en el diagn&#xf3;stico y tratamiento de la fibrosis pulmonar idiop&#xe1;tica. Datos del Registro de la Sociedad Espa&#xf1;ola de Neumolog&#xed;a y Cirug&#xed;a Tor&#xe1;cica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Open Respir Arch</MedlineTA><NlmUniqueID>9918591885806676</NlmUniqueID><ISSNLinking>2659-6636</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO">El objetivo de este estudio fue analizar el proceso diagn&#xf3;stico de los pacientes con fibrosis pulmonar idiop&#xe1;tica en Espa&#xf1;a, desde el inicio de los s&#xed;ntomas hasta el diagn&#xf3;stico y tratamiento antifibr&#xf3;tico, en relaci&#xf3;n con la publicaci&#xf3;n de las sucesivas gu&#xed;as de pr&#xe1;ctica cl&#xed;nica.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS">Estudio multic&#xe9;ntrico, observacional, ambispectivo, en el que se analizaron los pacientes incluidos en el registro de la fibrosis pulmonar idiop&#xe1;tica de la Sociedad Espa&#xf1;ola de Neumolog&#xed;a y Cirug&#xed;a Tor&#xe1;cica. Para ello se habilit&#xf3; un cuaderno electr&#xf3;nico de recogida de datos en la web de la sociedad. Se recogieron variables sociodemogr&#xe1;ficas y cl&#xed;nicas al diagn&#xf3;stico y seguimiento de los pacientes.</AbstractText><AbstractText Label="RESULTADOS">Desde enero de 2012 hasta diciembre de 2019 se incluyeron 1.064 pacientes, siendo finalmente analizados 929. El proceso diagn&#xf3;stico vari&#xf3; en funci&#xf3;n del a&#xf1;o en el que se realiz&#xf3; el diagn&#xf3;stico y el patr&#xf3;n radiol&#xf3;gico observado en la tomograf&#xed;a computarizada de alta resoluci&#xf3;n. En 244 (26,3%) pacientes, el diagn&#xf3;stico se realiz&#xf3; con tomograf&#xed;a computarizada de alta resoluci&#xf3;n de t&#xf3;rax y evaluaci&#xf3;n cl&#xed;nica. La biopsia quir&#xfa;rgica se utiliz&#xf3; hasta en el 50,2% de los casos diagnosticados antes del 2011, y en un 14,2% a partir de 2018. La mediana de tiempo que transcurre desde el inicio de los s&#xed;ntomas hasta el diagn&#xf3;stico es de 360 d&#xed;as (RIC 120-720), siendo mayor de 2 a&#xf1;os en el 21,0% de los pacientes. Recibieron tratamiento antifibr&#xf3;tico al 79,4% de los pacientes. El tiempo desde el diagn&#xf3;stico hasta el inicio del tratamiento fue de 309&#xa0;&#xb1;&#xa0;596,5 d&#xed;as, con una mediana de 49 (RIC 0-307).</AbstractText><AbstractText Label="CONCLUSIONES">El proceso diagn&#xf3;stico, incluyendo el tiempo hasta el diagn&#xf3;stico y el tipo de pruebas utilizadas, ha ido cambiando desde 2011 hasta 2019, probablemente debido el avance en la investigaci&#xf3;n cl&#xed;nica y la publicaci&#xf3;n de gu&#xed;as consenso diagn&#xf3;stico-terap&#xe9;uticas.</AbstractText><CopyrightInformation>&#xa9; 2024 Sociedad Espa&#xf1;ola de Neumolog&#xed;a y Cirug&#xed;a Tor&#xe1;cica (SEPAR). Published by Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Idiopathic pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">Interstitial lung disease</Keyword><Keyword MajorTopicYN="N">Multidisciplinary diagnosis team</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>18</Day><Hour>4</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39021619</ArticleId><ArticleId IdType="pmc">PMC11253673</ArticleId><ArticleId IdType="doi">10.1016/j.opresp.2024.100334</ArticleId><ArticleId IdType="pii">S2659-6636(24)00037-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xaubet A., Ancochea J., Morell F., Rodriguez-Arias J.M., Villena V., Blanquer R., et al. Spanish Group on Interstitial Lung Diseases, SEPAR Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15127977</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul B., Cottin V., Collard H.R., Valenzuela C. Variability in global prevalence of interstitial lung disease. Front Med (Lausanne). 2021;8:751181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8599270</ArticleId><ArticleId IdType="pubmed">34805219</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher T.M., Bendstrup E., Dron L., Langley J., Smith G., Khalid J.M., et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261998</ArticleId><ArticleId IdType="pubmed">34233665</ArticleId></ArticleIdList></Reference><Reference><Citation>Scadding J.G. Lung biopsy in the diagnosis of diffuse lung disease. BMJ. 1970;2:557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1700215</ArticleId><ArticleId IdType="pubmed">5535843</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5450933</ArticleId><ArticleId IdType="pubmed">21471066</ArticleId></ArticleIdList></Reference><Reference><Citation>Xaubet A., Ancochea J., Bollo E., Fern&#xe1;ndez-Fabrellas E., Franquet T., Molina-Molina M., et al. Normativa sobre el diagn&#xf3;stico y tratamiento de la fibrosis pulmonar idiop&#xe1;tica. Arch Bronconeumol. 2011;49:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">28292522</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G., Rochwerg B., Zhang Y., Garcia C.A., Azuma A., Behr J., et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3&#x2013;e19.</Citation><ArticleIdList><ArticleId IdType="pubmed">26177183</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghu G., Remy-Jardin M., Myers J.L., Richeldi L., Ryerson C.J., Lederer D.J., et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44&#x2013;e68.</Citation><ArticleIdList><ArticleId IdType="pubmed">30168753</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottin V., Martinez F.J., Smith V., Walsh S.L.F. Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: Current perspectives. Eur Respir Rev. 2022;31:220003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724802</ArticleId><ArticleId IdType="pubmed">38743511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer N., Prior T.S., Bendstrup E., Shaker S.B. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates. BMJ Open Respir Res. 2022;9:e001276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9263910</ArticleId><ArticleId IdType="pubmed">35798532</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder L.D., Mosher C., Holtze C.H., Lancaster L.H., Flaherty K.R., Noth I., et al. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO registry. BMJ Open Respir Res. 2020;7:e000567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337884</ArticleId><ArticleId IdType="pubmed">32624493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman T.W., van Es H.W., Biesma D.H., Grutters J.C. Potential interstitial lung abnormalities on chest X-rays prior to symptoms of idiopathic pulmonary fibrosis. BMC Pulm Med. 2022;22:329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426013</ArticleId><ArticleId IdType="pubmed">36038862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamas D.J., Kawut S.M., Bagiella E., Philip N., Arcasoy S.M., Lederer D.J. Delayed access and survival in idiopathic pulmonary fibrosis: A cohort study. Am J Respir Crit Care Med. 2011;184:842&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208648</ArticleId><ArticleId IdType="pubmed">21719755</ArticleId></ArticleIdList></Reference><Reference><Citation>King T.E., Bradford W.Z., Castro-Bernardini S., Fagan E.A., Glaspole I., Glassberg M.K., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">24836312</ArticleId></ArticleIdList></Reference><Reference><Citation>Richeldi L., du Bois R.M., Raghu G., Azuma A., Brown K.K., Costabel U., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071&#x2013;2082.</Citation><ArticleIdList><ArticleId IdType="pubmed">24836310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Fabrellas E., Molina-Molina M., Soriano J.B., Portal J.A.R., Ancochea J., Valenzuela C., et al. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: The SEPAR National Registry. Respir Res. 2019;20:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580511</ArticleId><ArticleId IdType="pubmed">31208406</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther A., Krauss E., Tello S., Wagner J., Paul B., Kuhn S., et al. The European IPF registry (eurIPFreg): Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018;19:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6064050</ArticleId><ArticleId IdType="pubmed">30055613</ArticleId></ArticleIdList></Reference><Reference><Citation>Behr J., Kreuter M., Hoeper M.M., Wirtz H., Klotsche J., Koschel D., et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: The INSIGHTS-IPF registry. Eur Respir J. 2015;46:186&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486374</ArticleId><ArticleId IdType="pubmed">25837040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuyts W.A., Dahlqvist C., Slabbynck H., Schlesser M., Gusbin N., Compere C., et al. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: The PROOF registry. BMJ Open Respir Res. 2018;5:e000331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6267319</ArticleId><ArticleId IdType="pubmed">30555708</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer L.G., Loughenbury M., Chaudhuri N., Spiteri M., Parfrey H. Idiopathic pulmonary fibrosis in the UK: Analysis of the British Thoracic Society electronic registry between 2013 and 2019. ERJ Open Res. 2021;7:00187&#x2013;2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836645</ArticleId><ArticleId IdType="pubmed">33532476</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajares V., Puzo C., Castillo D., Lerma E., Montero M.A., Ramos-Barb&#xf3;n D., et al. A diagnostic yield of transbronchial cryobiopsy in interstitial lung disease: A randomized trial. Respirology. 2014;19:900&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">24890124</ArticleId></ArticleIdList></Reference><Reference><Citation>Casoni G.L., Tomassetti S., Cavazza A., Colby T.V., Dubini A., Ryu J.H., et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. Plos One. 2014;9:e86716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3938401</ArticleId><ArticleId IdType="pubmed">24586252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Gonz&#xe1;lez F., Lucena C.M., Ram&#xed;rez J., S&#xe1;nchez M., Jimenez M.J., Xaubet A., et al. Cryobiopsy in the diagnosis of diffuse interstitial lung disease: Yield and cost-effectiveness analysis. Arch Bronconeumol. 2015;51:261&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">25454902</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascante J.A., Cebollero P., Herrero S., Yag&#xfc;e A., Echegoyen A., Elizalde J., et al. Transbronchial cryobiopsy in interstitial lung disease: Are we on the right path? J Bronchology Interv Pulmonol. 2016;23:204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">27261937</ArticleId></ArticleIdList></Reference><Reference><Citation>Echevarria-Uraga J.J., P&#xe9;rez-Izquierdo J., Garc&#xed;a-Garai N., G&#xf3;mez-Jim&#xe9;nez E., Aramburu-Ojembarrena A., Tena-Tudanca L., et al. Usefulness of an angioplasty balloon as selective bronchial blockade device after transbronchial cryobiopsy. Respirology. 2016;21:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">27254138</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara G., Carlson L., Palm A., Pesonen I.H.A., Li C.X., Wheelock &#xc5;., et al. Idiopathic pulmonary fibrosis in Sweden: Report from the first year of activity of the Swedish IPF-Registry. Eur Clin Respir J. 2016;3:31090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4841864</ArticleId><ArticleId IdType="pubmed">27105945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo H.E., Glaspole I., Grainge C., Goh N., Hopkins P.M.A., Moodley Y., et al. Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49:1601592.</Citation><ArticleIdList><ArticleId IdType="pubmed">28232409</ArticleId></ArticleIdList></Reference><Reference><Citation>Salisbury M.L., Conoscenti C.S., Culver D.A., Yow E., Neely M.L., Bender S., et al. Antifibrotic drug use in patients with idiopathic pulmonary fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020;17:1413&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640723</ArticleId><ArticleId IdType="pubmed">32574517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer N., Prior T.S., Bendstrup E., Wilcke T., Shaker S.B. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20:103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6534848</ArticleId><ArticleId IdType="pubmed">31126287</ArticleId></ArticleIdList></Reference><Reference><Citation>Herberts M.B., Teague T.T., Thao V., Sangaralingham L.R., Henk H.J., Hovde K.T., et al. Idiopathic pulmonary fibrosis in the United States: Time to diagnosis and treatment. BMC Pulm Med. 2023;23:281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10398946</ArticleId><ArticleId IdType="pubmed">37532984</ArticleId></ArticleIdList></Reference><Reference><Citation>Caro F., Buend&#xed;a-Rold&#xe1;n I., Noriega-Aguirre L., Alberti M.L., Amaral A., Arbo G., et al. Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical characteristics, evolution and treatment. Arch Bronconeumol. 2022;58:794&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">35798664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaunisto J., Kelloniemi K., Sutinen E., Hodgson U., Piilonen A., Kaarteenaho R., et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4541726</ArticleId><ArticleId IdType="pubmed">26285574</ArticleId></ArticleIdList></Reference><Reference><Citation>Assayag D., Garlick K., Johannson K.A., Fell C.D., Kolb M., Cox G., et al. Treatment initiation in patients with interstitial lung disease in Canada. Ann Am Thorac Soc. 2021;18:1661&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pubmed">33493425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolonics-Farkas A.M., &#x160;terclov&#xe1; M., Mogulkoc N., Lewandowska K., M&#xfc;ller V., H&#xe1;jkov&#xe1; M., et al. Differences in baseline characteristics and access to treatment of newly diagnosed patients with IPF in the EMPIRE countries. Front Med (Lausanne) 2021;8:729203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733326</ArticleId><ArticleId IdType="pubmed">35004713</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38889570</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8865</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Semergen</Title><ISOAbbreviation>Semergen</ISOAbbreviation></Journal><ArticleTitle>[Limitations, controversies and challenges of clinical practice guidelines on the pharmacological management of neuropathic pain].</ArticleTitle><Pagination><StartPage>102276</StartPage><MedlinePgn>102276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semerg.2024.102276</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1138-3593(24)00086-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alc&#xe1;ntara Montero</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Salud Trujillo, Consultorios de Herguijuela/Conquista de la Sierra, C&#xe1;ceres, Espa&#xf1;a; Grupo de Trabajo de Dolor y Cuidados Paliativos de SEMERGEN. Electronic address: a.alcantara.montero@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibor Vidal</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Centro de Salud Guillem de Castro, Valencia, Espa&#xf1;a; Grupo de Trabajo de Dolor y Cuidados Paliativos de SEMERGEN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><VernacularTitle>Limitaciones, controversias y desaf&#xed;os de las gu&#xed;as de pr&#xe1;ctica cl&#xed;nica sobre el manejo farmacol&#xf3;gico del dolor neurop&#xe1;tico.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Semergen</MedlineTA><NlmUniqueID>9610769</NlmUniqueID><ISSNLinking>1138-3593</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="Y">Neuralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>19</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>18</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38889570</ArticleId><ArticleId IdType="doi">10.1016/j.semerg.2024.102276</ArticleId><ArticleId IdType="pii">S1138-3593(24)00086-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38683515</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1669-9106</ISSN><JournalIssue CitedMedium="Internet"><Volume>84</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Medicina</Title><ISOAbbreviation>Medicina (B Aires)</ISOAbbreviation></Journal><ArticleTitle>[What conditions should the diagnosis and treatment guidelines meet, to be true clinical practice guidelines based on evidence?].</ArticleTitle><Pagination><StartPage>305</StartPage><EndPage>312</EndPage><MedlinePgn>305-312</MedlinePgn></Pagination><Abstract><AbstractText>The guides for diagnosis and treatment prepared by scientific medical societies constitute a very useful tool for the professional practice of the specialty. Supported by an updated bibliography, they represent material of enormous value with recommendations from experts on the various topics of the specialty. This article attempts to determine if they could be designed as "Evidence - Based Clinical Practice Guidelines" (CPG BE), for which the stages in their development and the requirements that they reviewed. The CPG BE are a "set of recommendations prepared systematically to help professionals and patients in making decisions about the most appropriate health care, selecting the most appropriate diagnostic and/or therapeutic options to address a problem of health or a specific clinical condition". Their objective is to improve the effectiveness, efficiency and safety of clinical decisions, and they can serve a basis for the development of health policies. The preparation of CPGs represents a complex process, which requires knowledge, experience and resources, both in time and money. Its robustness does not depend on who does it, but on how it is done. This implies the participation of technicians who provide the evaluation of the evidence using the GRADE method and the consideration of cost-effectiveness aspects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zerga</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Direcci&#xf3;n del &#xc1;rea M&#xe9;dica, Instituto de Oncolog&#xed;a &#xc1;ngel H. Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina. E-mail: melizerga@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>&#xbf;Qu&#xe9; condiciones deben reunir las gu&#xed;as de diagn&#xf3;stico y tratamiento para ser verdaderas gu&#xed;as de pr&#xe1;ctica clinica basadas en la evidencia?</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Medicina (B Aires)</MedlineTA><NlmUniqueID>0204271</NlmUniqueID><ISSNLinking>0025-7680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Las gu&#xed;as de diagn&#xf3;stico y tratamiento elaboradas por las sociedades cient&#xed;ficas m&#xe9;dicas, constituyen una herramienta muy &#xfa;til para el ejercicio profesional de la especialidad. Sustentadas en bibliograf&#xed;a actualizada, representan un material de enorme valor con recomendaciones de los expertos en los diversos temas de la especialidad. En el presente art&#xed;culo se intenta determinar si las mismas podr&#xed;an ser dise&#xf1;adas acerc&#xe1;ndolas lo m&#xe1;s estrechamente posible al formato de las Gu&#xed;as de Pr&#xe1;ctica Cl&#xed;nica Basadas en la Evidencia (GPC-BE), para lo cual se revisan las etapas en su elaboraci&#xf3;n y los requisitos que deber&#xed;an cumplir para ser consideradas como tales. Las GPC-BE son un "conjunto de recomendaciones elaboradas de forma sistem&#xe1;tica para ayudar a los profesionales y a los pacientes en la toma de decisiones sobre la atenci&#xf3;n sanitaria m&#xe1;s apropiada, seleccionando las opciones diagn&#xf3;sticas y/o terap&#xe9;uticas m&#xe1;s adecuadas en el abordaje de un problema de salud o una condici&#xf3;n cl&#xed;nica espec&#xed;fica". Su objetivo es mejorar la efectividad, la eficiencia y la seguridad de las decisiones cl&#xed;nicas, y pueden servir de base para la elaboraci&#xf3;n de pol&#xed;ticas de salud. La elaboraci&#xf3;n de las GPC representa un proceso complejo, que requiere conocimientos, experiencia y recursos tanto en tiempo como en dinero. Su robustez no depende de quienes la realizan, sino de c&#xf3;mo es realizada. Ello implica la participaci&#xf3;n de t&#xe9;cnicos que aporten la evaluaci&#xf3;n de la evidencia por el m&#xe9;todo GRADE, y la consideraci&#xf3;n de aspectos de costo-efectividad.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical practice guidelines</Keyword><Keyword MajorTopicYN="N">evidencebased guidelines</Keyword><Keyword MajorTopicYN="N">guides with GRADE methodology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>30</Day><Hour>15</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>29</Day><Hour>13</Hour><Minute>58</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>29</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38683515</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>